Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 42

    1.

    Germline mutations in HOXB13 and prostate-cancer risk.

    Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW, Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WB, Cooney KA.

    N Engl J Med. 2012 Jan 12;366(2):141-9.

    PMID:
    22236224
    [PubMed - indexed for MEDLINE]
    2.

    5α-Reductase inhibitors for prostate-cancer prevention.

    Kim J, Amos CI, Logothetis C.

    N Engl J Med. 2011 Dec 15;365(24):2340. No abstract available.

    PMID:
    22168662
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    One man at a time--resolving the PSA controversy.

    McNaughton-Collins MF, Barry MJ.

    N Engl J Med. 2011 Nov 24;365(21):1951-3. Epub 2011 Oct 26. No abstract available.

    PMID:
    22029758
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.

    Brett AS, Ablin RJ.

    N Engl J Med. 2011 Nov 24;365(21):1949-51. Epub 2011 Oct 26. No abstract available.

    PMID:
    22029759
    [PubMed - indexed for MEDLINE]
    Free Article
    5.

    Stratifying risk--the U.S. Preventive Services Task Force and prostate-cancer screening.

    Schröder FH.

    N Engl J Med. 2011 Nov 24;365(21):1953-5. Epub 2011 Oct 26. No abstract available.

    PMID:
    22029756
    [PubMed - indexed for MEDLINE]
    Free Article
    6.

    Clinical practice. Screening for prostate cancer.

    Hoffman RM.

    N Engl J Med. 2011 Nov 24;365(21):2013-9. Epub 2011 Oct 26. Review. No abstract available.

    PMID:
    22029754
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Radiotherapy and androgen deprivation for prostate cancer.

    Créhange G, Bolla M, Maingon P.

    N Engl J Med. 2011 Oct 6;365(14):1354; author reply 1354-5. No abstract available.

    PMID:
    21991967
    [PubMed - indexed for MEDLINE]
    8.

    Error occurred: cannot get document summary

    PMID:
    21864183

    9.

    Abiraterone and increased survival in metastatic prostate cancer.

    Berruti A, Pia A, Terzolo M.

    N Engl J Med. 2011 Aug 25;365(8):766; author reply 767-8. No abstract available.

    PMID:
    21864182
    [PubMed - indexed for MEDLINE]
    10.

    Abiraterone and increased survival in metastatic prostate cancer.

    Sonpavde G.

    N Engl J Med. 2011 Aug 25;365(8):766-7; author reply 767-8. No abstract available.

    PMID:
    21864181
    [PubMed - indexed for MEDLINE]
    11.

    Abiraterone and increased survival in metastatic prostate cancer.

    Parker C, Sartor O.

    N Engl J Med. 2011 Aug 25;365(8):767. No abstract available.

    PMID:
    21864180
    [PubMed - indexed for MEDLINE]
    12.

    Early prostate cancer--treat or watch?

    Froehner M, Wirth MP.

    N Engl J Med. 2011 Aug 11;365(6):568. No abstract available.

    PMID:
    21830974
    [PubMed - indexed for MEDLINE]
    13.

    Early prostate cancer--treat or watch?

    Shigeta K, Naito Y, Takano T.

    N Engl J Med. 2011 Aug 11;365(6):568-9. No abstract available.

    PMID:
    21830973
    [PubMed - indexed for MEDLINE]
    14.

    Early prostate cancer--treat or watch?

    Klotz L, Thompson I.

    N Engl J Med. 2011 Aug 11;365(6):569. No abstract available.

    PMID:
    21830972
    [PubMed - indexed for MEDLINE]
    15.

    Risk-based management of prostate cancer.

    D'Amico AV.

    N Engl J Med. 2011 Jul 14;365(2):169-71. No abstract available.

    PMID:
    21751910
    [PubMed - indexed for MEDLINE]
    16.

    Radiotherapy and short-term androgen deprivation for localized prostate cancer.

    Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU.

    N Engl J Med. 2011 Jul 14;365(2):107-18.

    PMID:
    21751904
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

    Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R.

    N Engl J Med. 2011 Jul 14;365(2):97-9. Epub 2011 Jun 15. No abstract available.

    PMID:
    21675880
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Expanding treatment options for metastatic prostate cancer.

    Antonarakis ES, Eisenberger MA.

    N Engl J Med. 2011 May 26;364(21):2055-8. No abstract available.

    PMID:
    21612475
    [PubMed - indexed for MEDLINE]
    19.

    Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.

    Smith MR, Zietman AL, Finkelstein JS, Wu CL.

    N Engl J Med. 2011 May 26;364(21):2044-51. No abstract available.

    PMID:
    21612474
    [PubMed - indexed for MEDLINE]
    20.

    Abiraterone and increased survival in metastatic prostate cancer.

    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators.

    N Engl J Med. 2011 May 26;364(21):1995-2005.

    PMID:
    21612468
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk